 RALEIGH, NC ACCESSWIRE April 19, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage company focused on rare and unmet needs in gastroenterology, announced today that the Company will enter into a collaboration with the Duke Clinical Research Institute DCRI to support the clinical development of 9 Meters candidate NM-002, a proprietary long-acting GLP-1 agonist, currently in Phase 2 development for short bowel syndrome SBS. SBS is a life-threatening orphan disease caused by a significant shortening of the gastrointestinal tract, leading to impaired nutrient absorption. 